{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T10:20:51Z","timestamp":1787998851869,"version":"build-2784847793"},"reference-count":41,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,1,31]],"date-time":"2017-01-31T00:00:00Z","timestamp":1485820800000},"content-version":"vor","delay-in-days":30,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Deutsche Derma Gesell"],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Pyoderma gangrenosum (PG) is an orphan disease. While research on such disorders is based on only few randomized multicenter as well as retrospective studies, most of the data comes from case series of small patient groups. Apart from topical and intralesional therapeutic options for early stages and mild disease courses, treatment predominantly involves systemic therapeutic agents. Besides systemic corticosteroids and cyclosporine A (CsA), options also include intravenous immunoglobulins (IVIG) and biologics such as the TNF\u03b1 inhibitors infliximab, adalimumab, and etanercept; the interleukin (IL) 12\/23 antibody ustekinumab; the IL\u20101 receptor antagonist anakinra; and the IL\u20101\u03b2 antibody canakinumab. The best evidence\u2010based study data is available for CsA, prednisolone, and infliximab; the latter especially in patients with concomitant ulcerative colitis or Crohn's disease. A response to IVIG and canakinumab has been reported in smaller case series. First described by Brocq almost 100 years ago, it was soon recognized that PG did in fact require treatment. To this day, however, such treatment remains a clinical challenge. Despite the severe \u2013 albeit rare \u2013clinical picture, improvement in therapeutic options may be expected in the future, primarily due to further clinical studies \u2013 especially with a greater number of patients, a better understanding of the etiopathogenesis, as well as the use of modern targeted therapies with higher efficacy and a lower rate of side effects than conventional immunosuppressants such as prednisolone and CsA.<\/jats:p>","DOI":"10.1111\/ddg.13173","type":"journal-article","created":{"date-parts":[[2017,1,31]],"date-time":"2017-01-31T15:34:55Z","timestamp":1485876895000},"page":"34-40","source":"Crossref","is-referenced-by-count":20,"title":["Treatment options for pyoderma gangrenosum"],"prefix":"10.1111","volume":"15","author":[{"given":"Sven R.","family":"Quist","sequence":"first","affiliation":[{"name":"Department of Dermatology and Venereology Otto von Guericke University  Magdeburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luise","family":"Kraas","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology Otto von Guericke University  Magdeburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,1,31]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-8-136"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.05.030"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.104515"},{"key":"e_1_2_8_5_1","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/ddg.12822","article-title":"Pain and pain management in dermatology","volume":"13","author":"Beiteke U","year":"2015","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_8_6_1","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/ddg.12401","article-title":"Diagnostic criteria for pyoderma gangrenosum: results of a survey among dermatologic wound experts in Germany","volume":"12","author":"Al Ghazal P","year":"2014","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v1.i2.74"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-0960.2007.00344.x"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/11.8.961"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14037"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12394"},{"key":"e_1_2_8_12_1","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/ddg.12830","article-title":"Pyoderma gangrenosum\u2010like necrotizing panniculitis associated with alpha\u20101 antitrypsin deficiency: a lethal course","volume":"13","author":"Vigl K","year":"2015","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.12585"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.10.006"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2006.03133.x"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-481X.2010.00725.x"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/120347541201600503"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2007.02280.x"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/095466301750163518"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2013.06.003"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-198512000-00011"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/ced.12361"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00105-011-2269-8"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.09.009"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.09.009"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2005.05022.x"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.074815"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h2958"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2008"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03199.x"},{"key":"e_1_2_8_31_1","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1684\/ejd.2013.2018","article-title":"Pyoderma gangrenosum and concomitant hidradenitis suppurativa \u2013 rapid response to canakinumab (anti\u2010IL\u20101beta)","volume":"23","author":"Jaeger T","year":"2013","journal-title":"Eur J Dermatol"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/ced.12585"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.04.045"},{"key":"e_1_2_8_34_1","first-page":"1","article-title":"Certolizumab pegol \u2013 A new therapeutic option for refractory disseminated pyoderma gangrenosum associated with Crohn's disease","author":"Hurabielle C","year":"2015","journal-title":"J Dermatolog Treat"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-013-2762-2"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2003.07581.x"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-012-0006-6"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0540"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08217.x"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08433.x"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2010.328"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2011.168"}],"container-title":["JDDG: Journal der Deutschen Dermatologischen Gesellschaft"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fddg.13173","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ddg.13173","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T11:56:53Z","timestamp":1696247813000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ddg.13173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.1111\/ddg.13173"],"URL":"https:\/\/doi.org\/10.1111\/ddg.13173","archive":["Portico"],"relation":{},"ISSN":["1610-0379","1610-0387"],"issn-type":[{"value":"1610-0379","type":"print"},{"value":"1610-0387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1]]}}}